Ignite Creation Date:
2025-12-24 @ 9:38 PM
Ignite Modification Date:
2026-04-02 @ 2:05 AM
Study NCT ID:
NCT02654132
Status:
COMPLETED
Last Update Posted:
2022-11-01
First Post:
2015-12-31
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-03-18
Start Date Type:
ACTUAL
Primary Completion Date:
2018-01-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-10-21
Completion Date Type:
ACTUAL
First Submit Date:
2015-12-31
First Submit QC Date:
None
Study First Post Date:
2016-01-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-01-17
Results First Submit QC Date:
None
Results First Post Date:
2019-06-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-05
Last Update Post Date:
2022-11-01
Last Update Post Date Type:
ACTUAL